On Monday, Shares of Fiat Chrysler Automobiles NV (NYSE:FCAU), gained 1.75% to $13.96.
Fiat Chrysler Automobiles, declared that its partner FCA US LLC (“FCA US”) redeemed all of its outstanding 8 ¼% Secured Senior Notes due 2021 (the “Notes”) on December 21, 2015. The Notes were redeemed at a price equal to the $3,080,000,000 aggregate principal amount plus accrued and unpaid interest and the applicable “make-whole” premium.
As a result of the redemption, FCA US will no longer file periodic reports with the U.S. Securities and Exchange Commission (“SEC”) or host a quarterly webcast and analyst call. FCA’s SEC reporting obligations remain unchanged.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Shares of Opko Health Inc. (NYSE:OPK), inclined 2.20% to $10.20, during its last trading session.
OPKO Health, Inc. (OPK) through its partner GeneDx, declared results from the largest published study to date of patients who received hereditary genetic testing with Next Generation Sequencing (NGS) cancer panels. The study, “Pathogenic and Likely Pathogenic Variant Prevalence among the First 10,000 Patients Referred for Next Generation Cancer Panel Testing,” was published in the December 2015 issue of Genetics in Medicine. GeneDx’s analysis of the data generated from the first 10,030 patients highlights the clinical utility of testing for multiple cancer genes to identify variants that would not have been identified through formerly used testing methods. The patients, who were referred for testing between August, 2013 and October, 2014, underwent genetic testing for panels of genes associated with hereditary cancer.
While many patients were found to carry pathogenic or likely pathogenic variants in well-established, high-risk cancer genes, about half of the pathogenic variants identified were in genes with moderate risk and in recently identified cancer genes. Notably, among women with breast cancer, 50% of positive findings were in genes other than BRCA1 or BRCA2. Additionally, several individuals had pathogenic variants in high-risk genes that were somewhat unpredictable, so clinical presentation alone might not have prompted testing for these genes.
“We believe that molecular diagnostic testing for panels containing multiple genes are significantly more accurate in determine the heritable factors which improvement the risk of cancer, and may permit more tailored treatment for cancer patients and screening for their family members,” said Sherri Bale, PhD, FACMG, Co-Founder and Managing Director of GeneDx. “Our experience, based on a large database of patients, demonstrates that multi-gene panels have the potential to identify pathogenic variants in genes that would not typically have been tested and most likely would have been missed. This study provides important empirical data for clinical decision-making when choosing between single genes and NGS cancer panel testing for a variety of cancers.”
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
Finally, Southern Co (NYSE:SO), ended its last trade with 0.08% gain, and closed at $46.24.
Southern Company partner Southern Generation Technologies has signed a letter of intent with South Korean company Alps Energy and Kellogg, Brown & Root, LLC (KBR) to evaluate the deployment of the company’s proprietary coal gasification technology at the new, 1,000-megawatt (MW) Alps Energy power plant in the Saemangeum Industry & Research Area in South Korea. The agreement underscores the noteworthy international interest in Transport Integrated Gasification – or TRIG™ – the 21st century coal technology at the center of Southern Company partner Mississippi Power’s Kemper County energy facility.
Jointly developed by Southern Company and KBR, TRIG™ is designed to generate electricity from low-rank coal with resulting carbon emissions better than a similarly sized natural gas plant. At least 65 percent of the Kemper project’s carbon emissions are predictable to be captured and repurposed through improved oil recovery, increasing domestic oil production.
“Southern Company is committed to developing real solutions to efficiently generate electricity using all of our domestic energy resources,” said Southern Company Chairman, President and CEO Thomas A. Fanning. “By deploying TRIG™ for the first time at the Kemper County energy facility, we are creating a better energy future and improving America’s energy security. Our partnership with South Korea’s Alps Energy is a continuation of our long-standing commitment to delivering energy solutions that can benefit customers and communities across the U.S. and around the world.”
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
